122 related articles for article (PubMed ID: 11040045)
1. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41.
O'Keefe BR; Shenoy SR; Xie D; Zhang W; Muschik JM; Currens MJ; Chaiken I; Boyd MR
Mol Pharmacol; 2000 Nov; 58(5):982-92. PubMed ID: 11040045
[TBL] [Abstract][Full Text] [Related]
2. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
Mori T; Boyd MR
Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
[TBL] [Abstract][Full Text] [Related]
3. High throughput screening for cyanovirin-N mimetics binding to HIV-1 gp41.
Beutler JA; McMahon JB; Johnson TR; O'Keefe BR; Buzzell RA; Robbins D; Gardella R; Wilson J; Boyd MR
J Biomol Screen; 2002 Apr; 7(2):105-10. PubMed ID: 12006108
[TBL] [Abstract][Full Text] [Related]
4. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins.
Shenoy SR; O'Keefe BR; Bolmstedt AJ; Cartner LK; Boyd MR
J Pharmacol Exp Ther; 2001 May; 297(2):704-10. PubMed ID: 11303061
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9.
Chen YH; Ebenbichler C; Vornhagen R; Schulz TF; Steindl F; Böck G; Katinger H; Dierich MP
AIDS; 1992 Jun; 6(6):533-9. PubMed ID: 1388873
[TBL] [Abstract][Full Text] [Related]
6. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
[TBL] [Abstract][Full Text] [Related]
7. Development of a cyanovirin-N-HIV-1 gp120 binding assay for high throughput screening of natural product extracts by time-resolved fluorescence.
McMahon JB; Beutler JA; O'Keefe BR; Goodrum CB; Myers MA; Boyd MR
J Biomol Screen; 2000 Jun; 5(3):169-76. PubMed ID: 10894760
[TBL] [Abstract][Full Text] [Related]
8. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.
Mariner JM; McMahon JB; O'Keefe BR; Nagashima K; Boyd MR
Biochem Biophys Res Commun; 1998 Jul; 248(3):841-5. PubMed ID: 9704015
[TBL] [Abstract][Full Text] [Related]
9. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.
Boyd MR; Gustafson KR; McMahon JB; Shoemaker RH; O'Keefe BR; Mori T; Gulakowski RJ; Wu L; Rivera MI; Laurencot CM; Currens MJ; Cardellina JH; Buckheit RW; Nara PL; Pannell LK; Sowder RC; Henderson LE
Antimicrob Agents Chemother; 1997 Jul; 41(7):1521-30. PubMed ID: 9210678
[TBL] [Abstract][Full Text] [Related]
10. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.
Mori T; Shoemaker RH; Gulakowski RJ; Krepps BL; McMahon JB; Gustafson KR; Pannell LK; Boyd MR
Biochem Biophys Res Commun; 1997 Sep; 238(1):218-22. PubMed ID: 9299482
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 gp41 binds to several proteins on the human B-cell line, Raji.
Chen YH; Böck G; Vornhagen R; Steindl F; Katinger H; Dierich MP
Mol Immunol; 1993 Sep; 30(13):1159-63. PubMed ID: 8413320
[TBL] [Abstract][Full Text] [Related]
12. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120.
Bewley CA; Otero-Quintero S
J Am Chem Soc; 2001 May; 123(17):3892-902. PubMed ID: 11457139
[TBL] [Abstract][Full Text] [Related]
13. The human monocyte cell line U937 binds HIV-1 gp41 by proteins of 37, 45, 49, 62 and 92 kDa.
Chen YH; Böck G; Vornhagen R; Steindl F; Katinger H; Dierich MP
Immunol Lett; 1993 Jul; 37(1):41-5. PubMed ID: 8225405
[TBL] [Abstract][Full Text] [Related]
14. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of anti-HIV peptides from Dorstenia contrajerva and Treculia obovoidea.
Bokesch HR; Charan RD; Meragelman KM; Beutler JA; Gardella R; O'Keefe BR; McKee TC; McMahon JB
FEBS Lett; 2004 Jun; 567(2-3):287-90. PubMed ID: 15178338
[TBL] [Abstract][Full Text] [Related]
16. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies.
Mondor I; Moulard M; Ugolini S; Klasse PJ; Hoxie J; Amara A; Delaunay T; Wyatt R; Sodroski J; Sattentau QJ
Virology; 1998 Sep; 248(2):394-405. PubMed ID: 9721247
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein.
Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T
Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709
[TBL] [Abstract][Full Text] [Related]
18. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).
Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN
Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101
[TBL] [Abstract][Full Text] [Related]
19. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.
Ebenbichler CF; Thielens NM; Vornhagen R; Marschang P; Arlaud GJ; Dierich MP
J Exp Med; 1991 Dec; 174(6):1417-24. PubMed ID: 1744579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
